Skip to main content

Advertisement

SpringerLink
Log in

Management of Hypertension in the Elderly

  • Elderly + Heart Disease (K Dharmarajan, Section Editor)
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

Recommendations for the management of hypertension in the elderly are largely consistent with the exception of the 2013 Joint National Committee (JNC) 8 guidelines that recommend lowering systolic blood pressure (SBP) in persons aged ≥60 years to <150 mmHg if they do not have diabetes mellitus or chronic kidney disease. In contrast, I concur with the minority view from JNC 8 which recommends a SBP goal in these persons aged 60 to 79 years of <140 mmHg. This view is consistent with the 2011 American College of Cardiology/American Heart Association (ACC/AHA) guidelines that also recommend a SBP goal of 140 to 145 mmHg if tolerated in adults aged ≥80 years. ACC/AHA consensus guidelines use the totality of evidence in addition to randomized controlled trial data. These guidelines are also consistent with treatment recommendations from numerous other societies that recommend SBP goals of <140 mmHg in persons aged 60 to 79 years and <150 mmHg in persons aged ≥80 years. Hypertension is currently under-treated in the elderly, and relaxation of ACC/AHA guidelines by JNC 8 will result in substantially more cardiovascular events. Randomized clinical trial studies on treatment of essential hypertension or secondary hypertension in frail elderly persons have not been performed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57:2037–114. These guidelines recommend that the systolic blood pressure be lowered to less than 140 mmHg in persons aged 60–79 years and to 140 to 145 mmHg if tolerated in persons aged 80 years and older.

    Article  PubMed  Google Scholar 

  2. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.

    Article  Google Scholar 

  3. Perry Jr HM, Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. The Systolic Hypertension in the Elderly Program (SHEP). JAMA. 2000;284:465–71.

    Article  PubMed  Google Scholar 

  4. Kostis JB, Davis BR, Cutler J, Grimm Jr RH, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212–6.

    Article  CAS  PubMed  Google Scholar 

  5. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Eng J Med. 2008;358:1887–98.

    Article  CAS  Google Scholar 

  6. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi:10.1136/bmj.b1665.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219. These hypertension guidelines recommend lowering the systolic blood pressure to less than 140 mmHg in persons aged 60 to 79 years and in persons aged 80 years and older with a systolic blood pressure of 160 mmHg or higher to between 140–150 mmHg provided they are in good physical and mental conditions.

    Article  PubMed  Google Scholar 

  8. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20. These guidelines recommend lowering the systolic blood pressure in persons aged 60 years or older to less than 150 mmHg if they do not have diabetes mellitus or chronic kidney disease and to less than 140 mmHg if they have diabetes mellitus or chronic kidney disease.

    Article  CAS  PubMed  Google Scholar 

  9. Wright Jr JT, Fine LJ, Lackland DT, Ogedegbe G, Dennison-Himmelfarb C. Evidence supporting a systolic blood pressure goal of less than 150 mmHg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014;160:499–503. This minority report from JNC 8 recommends that the systolic blood pressure goal in persons aged 60 to 79 years with hypertension without diabetes mellitus or chronic kidney disease should be lowered to less than 140 mmHg.

    Article  PubMed  Google Scholar 

  10. Hackam DG, Quinn RR, Ravani P, Rabi DM, Dasgupta K, Daskalopoulou SS, et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2013;29:528–42. These guidelines recommend lowering the systolic blood pressure to less than 140 mmHg in elderly persons younger than 80 years of age and to less than 150 mmHg in persons aged 80 years and older.

    Article  PubMed  Google Scholar 

  11. National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults. London: National Institute for Health and Clinical Excellence. 2011. These guidelines recommend lowering the systolic blood pressure to less than 140 mmHg in elderly persons younger than 80 years.

  12. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community. A statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;16:14–26. These guidelines recommend lowering the blood pressure to less than 140/90 mmHg in persons aged 80 years and younger and to less than 150/90 mmHg in persons older than 80 years unless these persons have diabetes mellitus or chronic kidney disease when a target goal of less than 140/90 mmHg should be considered.

    Google Scholar 

  13. Krakoff LR, Gillespie RL, Ferdinand KC, Fergus IV, Akinboboye O, Williams KA, et al. 2014 hypertension recommendations from the Eighth Joint National Committee panel members raise concerns for elderly black and female populations. J Am Coll Cardiol. 2014;64:394–402. The Association of Black Cardiologists and the Working Group on Women’s Cardiovascular Health also support a systolic blood pressure goal of less than 140 mmHg in persons aged 60 to 79 years and of less than 150 mmHg in persons aged 80 years and older.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, et al. AHA/ACC/ASH scientific statement. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Circulation 2015; first published on March 31, 2015 as doi:10.1161/CIR.0000000000000207. These guidelines state that the optimal blood pressure in patients with coronary artery disease is less than 140/90 mmHg.

  15. Banach M, Bromfield S, Howard G, Howard VJ, Zanchetti A, Aronow WS, et al. Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. Int J Cardiol. 2014;176:219–26.

    Article  PubMed  Google Scholar 

  16. Bangalore S, Gong Y, Cooper-DeHoff RM, Pepine CJ, Messerli FH. 2014 Eighth Joint National Committee panel recommendation for blood pressure targets revisited: results from the INVEST study. J Am Coll Cardiol. 2014;64:784–93.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21–181.

    Article  PubMed  Google Scholar 

  18. Aronow WS, Ahmed MI, Ekundayo OJ, Allman RM, Ahmed A. A propensity-matched study of the association of PAD with cardiovascular outcomes in community-dwelling older adults. Am J Cardiol. 2009;103:130–5.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294:466–72.

    Article  CAS  PubMed  Google Scholar 

  20. Navar-Boggan AM, Pencina MJ, Williams K, Sniderman AD, Peterson ED. Proportion of US adults potentially affected by the 2014 hypertension guideline. JAMA. 2014;311:1424–9.

    Article  CAS  PubMed  Google Scholar 

  21. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo Jr JL, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761–88.

    Article  PubMed  Google Scholar 

  22. Aronow WS. Hypertension guidelines. Hypertension. 2011;58:347–8.

    Article  PubMed  Google Scholar 

  23. Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010;122:2142–51.

    Article  CAS  PubMed  Google Scholar 

  24. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff Jr DC, Grimm Jr RH, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.

    Article  Google Scholar 

  26. Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124:1727–36.

    Article  PubMed  Google Scholar 

  27. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74–83.

    Article  PubMed  Google Scholar 

  28. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541–8.

    Article  PubMed  Google Scholar 

  29. Appel LJ, Wright Jr JT, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918–29.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, et al. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension. 1997;29:641–50.

    Article  CAS  PubMed  Google Scholar 

  31. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-lordache B, Turturro M, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939–46.

    Article  PubMed  Google Scholar 

  32. Ovbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, et al. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA. 2011;306:2137–44.

    Article  CAS  PubMed  Google Scholar 

  33. Banach M, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI, et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107:1208–14.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Chiong JR, Aronow WS, Khan IA, Nair CK, Vijavaraghavan K, Dart RA, et al. Secondary hypertension: current diagnosis and treatment. Int J Cardiol. 2008;124:6–21.

    Article  PubMed  Google Scholar 

  35. ASTRAL Investigators, Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361:1953–62.

    Article  Google Scholar 

  36. Bax L, Woittiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med. 2009;150:840–8.

    Article  PubMed  Google Scholar 

  37. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370:13–22.

    Article  CAS  PubMed  Google Scholar 

  38. Banach M, Serban C, Aronow WS, Rysz J, Dragan S, Lerma EV, et al. Lipid, blood pressure and kidney update 2013. Int Urol Nephrol. 2014;46:947–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–26.

    Article  PubMed  Google Scholar 

  40. Myat A, Redwood SR, Quereshi AC, Spertus JA, Williams B. Resistant hypertension. BMJ. 2012;345, e7473. doi:10.1136/bmj.e7473 (published 20 November 2012).

    Article  PubMed  Google Scholar 

  41. Pimenta E, Calhoun DA. Resistant hypertension. Incidence, prevalence, and prognosis. Circulation. 2012;125:1594–6.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Gandelman G, Aronow WS, Varma R. Prevalence of adequate blood pressure control in self-pay or Medicare patients versus Medicaid or private insurance patients with systemic hypertension followed in a university cardiology or general medicine clinic. Am J Cardiol. 2004;94:815–6.

    Article  PubMed  Google Scholar 

  43. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839–45.

    Article  CAS  PubMed  Google Scholar 

  44. Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet. 2012;380:591–600.

    Article  CAS  PubMed  Google Scholar 

  45. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7.

    Article  Google Scholar 

  46. Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126:2976–82.

    Article  CAS  PubMed  Google Scholar 

  47. Davis MI, Filion KB, Zhang D, Eisenberg MJ, Afilalo J, Schiffrin EL, et al. Effectiveness of renal denervation therapy for resistant hypertension. J Am Coll Cardiol. 2013;62:231–41.

    Article  PubMed  Google Scholar 

  48. Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Bohm M, Campese VM, et al. International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62:2031–45.

    Article  PubMed  Google Scholar 

  49. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:393–401.

    Article  Google Scholar 

  50. Bakris GL, Townsend RR, Liu M, Cohen SA, D’Agostino R, Flack JM, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014;64:1071–8.

    Article  PubMed  Google Scholar 

  51. Aronow WS. Multiple blood pressure medications and mortality among elderly individuals. JAMA. 2015;313:1362–3.

    Article  CAS  PubMed  Google Scholar 

  52. Benetos A, Labat C, Rossignol P, Fay R, Rolland Y, Valbusa F, et al. Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE study. JAMA Intern Med. doi:10.1001/jamainternmed. 2014.8012.

  53. Banach M, Aronow WS. Blood pressure J curve. Curr Hypertens Rep. 2012;14:556–66.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

The author declares that he has no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Cardiology Division, New York Medical College, Macy Pavilion, Room 138, Valhalla, NY, 10595, USA

    Wilbert S. Aronow

Authors
  1. Wilbert S. Aronow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wilbert S. Aronow.

Additional information

This article is part of the Topical Collection on Elderly + Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aronow, W.S. Management of Hypertension in the Elderly. Curr Cardiovasc Risk Rep 9, 41 (2015). https://doi.org/10.1007/s12170-015-0469-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s12170-015-0469-y

Keywords

Search

Navigation